Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $316.09 and traded as low as $310.52. Charles River Laboratories International shares last traded at $314.2860, with a volume of 1,154,115 shares trading hands.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on CRL shares. TD Cowen reiterated a “buy” rating and issued a $388.00 target price on shares of Charles River Laboratories International in a report on Wednesday, November 11th. Zacks Research downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Evercore set a $330.00 price objective on Charles River Laboratories International in a research note on Friday, September 25th. Morgan Stanley raised their price target on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Finally, Jefferies Financial Group raised their target price on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $311.67.
View Our Latest Research Report on CRL
Charles River Laboratories International Price Performance
The company has a market cap of $15.06 billion, a P/E ratio of 345.37, a P/E/G ratio of 2.84 and a beta of 1.36. The company’s 50-day moving average price is $316.09 and its two-hundred day moving average price is $231.19. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The business had revenue of $982.73 million during the quarter, compared to the consensus estimate of $960.36 million. During the same period last year, the firm earned $2.43 earnings per share. The company’s revenue for the quarter was down 2.2% compared to the same quarter last year. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.
Insider Activity at Charles River Laboratories International
In related news, EVP Shannon Parisotto sold 2,156 shares of the stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,655,578.87. This represents a 30.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James C. Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the sale, the director directly owned 31,596 shares in the company, valued at $9,478,800. The trade was a 51.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 60,740 shares of company stock valued at $19,528,128. Insiders own 1.30% of the company’s stock.
Institutional Investors Weigh In On Charles River Laboratories International
Several hedge funds and other institutional investors have recently made changes to their positions in CRL. State Street Corp increased its holdings in shares of Charles River Laboratories International by 281.6% during the 3rd quarter. State Street Corp now owns 14,226,815 shares of the medical research company’s stock worth $4,197,053,000 after purchasing an additional 10,498,247 shares during the period. Aberdeen Group plc boosted its stake in Charles River Laboratories International by 483.6% during the third quarter. Aberdeen Group plc now owns 792,576 shares of the medical research company’s stock worth $233,818,000 after buying an additional 656,777 shares in the last quarter. Bank of America Corp DE increased its holdings in Charles River Laboratories International by 5.0% in the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after buying an additional 54,500 shares during the period. First Trust Advisors LP lifted its holdings in shares of Charles River Laboratories International by 1,943.7% during the 3rd quarter. First Trust Advisors LP now owns 626,401 shares of the medical research company’s stock worth $184,795,000 after acquiring an additional 595,750 shares during the period. Finally, Amundi boosted its position in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after acquiring an additional 492,301 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.
Charles River Laboratories International Company Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Read More
- Five stocks we like better than Charles River Laboratories International
- Growing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?
- Keysight Technologies: The Tollbooth on the Technology Superhighway
- Zscaler Got a Boost From Palo Alto, But Now It Has to Deliver.
- Bargain Hunting: Why Off-Price Retail Is Winning
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
